Abstract

BackgroundStaphylococcus aureus is a major human pathogen and strains resistant to existing treatments continue to emerge. Development of novel treatments is therefore important. Antimicrobial peptides represent a source of potential novel antibiotics to combat resistant bacteria such as Methicillin-Resistant Staphylococcus aureus (MRSA). A promising antimicrobial peptide is ranalexin, which has potent activity against Gram-positive bacteria, and particularly S. aureus. Understanding mode of action is a key component of drug discovery and network biology approaches enable a global, integrated view of microbial physiology, including mechanisms of antibiotic killing. We developed a systems-wide functional association network approach to integrate proteome and transcriptome profiles, enabling study of drug resistance and mode of action.ResultsThe functional association network was constructed by Bayesian logistic regression, providing a framework for identification of antimicrobial peptide (ranalexin) response modules from S. aureus MRSA-252 transcriptome and proteome profiling. These signatures of ranalexin treatment revealed multiple killing mechanisms, including cell wall activity. Cell wall effects were supported by gene disruption and osmotic fragility experiments. Furthermore, twenty-two novel virulence factors were inferred, while the VraRS two-component system and PhoU-mediated persister formation were implicated in MRSA tolerance to cationic antimicrobial peptides.ConclusionsThis work demonstrates a powerful integrative approach to study drug resistance and mode of action. Our findings are informative to the development of novel therapeutic strategies against Staphylococcus aureus and particularly MRSA.

Highlights

  • Staphylococcus aureus is a major human pathogen and strains resistant to existing treatments continue to emerge

  • Transcriptome and proteome profiling were applied to identify changes in the ranalexin exposed Methicillin-Resistant Staphylococcus aureus (MRSA)-252 cultures compared to controls (Methods)

  • Overlap in Gene Ontology (GO) [27] annotation was observed for these datasets there were only a few cases of direct overlap at the gene level

Read more

Summary

Introduction

Staphylococcus aureus is a major human pathogen and strains resistant to existing treatments continue to emerge. Antimicrobial peptides represent a source of potential novel antibiotics to combat resistant bacteria such as Methicillin-Resistant Staphylococcus aureus (MRSA). A promising antimicrobial peptide is ranalexin, which has potent activity against Gram-positive bacteria, and S. aureus. Strains that are resistant to existing treatments continue to emerge and community-associated MRSA is a major global problem [3,4,6,7,8,9,10]. Antimicrobial peptides (AMPs) are a potential source of novel antibiotics that may be developed to combat resistant bacteria such as MRSA [11]. Ranalexin has potent activity against Gram-positive bacteria in vitro, Staphylococcus aureus [14]. Ranalexin offers therapeutic potential against staphylococcal infections, including MRSA

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.